NYSE · Healthcare
Cencora, Inc. (COR)
As-reported financials and recent SEC filings for Cencora, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$321.33B
Net income
$1.55B
Net margin
0.5%
Diluted EPS
$7.96
ROE
89.0%
P/E (TTM)
21.6×
Market cap
$54.80B
Debt / equity
4.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B |
| Gross profit | $11.48B | $9.91B | $8.96B | $8.30B | $6.94B |
| Operating income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B |
| Net income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B |
| Diluted EPS | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SD2026-05-29
View on EDGAR →8-K2026-05-29
View on EDGAR →42026-05-28
View on EDGAR →10-Q2026-05-06
View on EDGAR →8-K2026-05-06
View on EDGAR →42026-05-05
View on EDGAR →42026-05-05
View on EDGAR →42026-05-05
View on EDGAR →Go deeper on COR
Search Cencora, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.